The HPV testing market size to cross USD 1.1 billion by 2025, growing at a CAGR of 12% during the forecast period. The increased procurement of the latest generation HPV testing analyzers and test kits, coupled with the high prevalence of HPV infections and cancers, especially cervical and vaginal, influences the growth of the global HPV testing market. Traditionally, cervical cancer screening was based on cervical cytology or pap test. However, in recent years, several countries and global health bodies have recommended the inclusion of HPV tests for cervical and pre-cancer screening programs, which is likely to boost the market.
The demand for new innovative testing consumables and instruments using advanced techniques such as the HPV mRNA test, which promotes accurate and sensitive diagnostic outcomes, is driving the market growth. Further, with the availability of positive clinical evidence, demonstrating the superiority of the latest generation advanced testing devices, end-users will become increasingly aware of clinical benefits and rapidly adopt these tests as an essential screening tool for cervical cancer screening. Therefore, the improvement in patient management, favorable government initiatives for primary screening, and the rising awareness of advanced testing in developed and developing economies are increasing the adoption globally.
- Approximately 570,000 cases of human papillomavirus cervical cancer cases are diagnosed annually across the globe. Cervical cancer in the US is the third most common disease among women, with over 14,065 new cases reported every year.
- About 85% of diagnosed cervical cancers and related deaths occur among women living in lower-middle-income countries. China and India have the highest numbers of people with cervical cancers.
- The growing awareness related to HPV testing for cervical cancer screening is contributing to the uptake of instruments and consumables.
- Vendors need to focus on the development of mRNA HPV testing for high sensitivity and accuracy.
HPV TESTING MARKET SEGMENTATION
This research report includes detailed segmentation by
INSIGHTS BY PRODUCTS
The consumables segment is growing due to the high adoption of advanced testing kits, reagents, and other related consumables to detect and screen cervical cancers globally. The segment is also growing at a fast rate due to the recurring purchase by end-users to perform HPV tests. These screening tests are likely to gain wide acceptance in emerging economies. The growth is due to favorable government initiatives and the rise in consumer spending power. Therefore, market players are focusing on significant product launches in a low resource setting of emerging countries, thereby boosting the segment growth.
The instruments segment is growing at a slow pace as the procurement of analyzers is capital intensive and the purchasing decision depends on financial resources and budget allocations. However, the increasing availability of automated and compact analyzers/instruments has significantly improved the efficiency and quality of end-user operations. Automation and integration of several diagnostic platforms have led to the introduction of innovative diagnostic analyzers. This is driving the growth of the segment during the forecast period.
INSIGHTS BY APPLICATION
The cervical cancer application segment accounted for 80% market share of the global HPV testing market. The cervical application segment is growing on account of the rise in cervical cancer incidences. The launch of screening products in low resource countries is expected to drive the cervical application segment during the upcoming years. In the US region, HPV self-sampling is emerging as a potential cancer screening strategy. This is likely to contribute to market growth.
The application of HPV testing for vaginal cancer offers powerful negative predictive values. Therefore, the detection of infection with a high-risk HPV, which produce visible signs, is a powerful tool for vaginal cancer screening. The benefit of HPV testing, rising vaginal cancer, and innovative testing devices are driving the growth of the vaginal application segment.
INSIGHTS BY END-USERS
In 2019, the standard reference laboratories segment accounted for 40% of the global HPV testing market. The standard reference laboratories help in improving overall diagnostic outcomes.
Healthcare professionals in hospitals use HPV testing as a screening procedure for cervical and other related cancers. The hospital segment is likely to grow at the fastest CAGR during the forecast period. A majority of patients with high-risk symptoms prefer visiting hospitals for diagnosis due to advanced infrastructure facilities.
The physicians’ office and clinic segment is expected to grow mainly on account of the growing prevalence of cervical cancers worldwide. The market is growing at a healthy rate with 12% CAGR during the forecast period. Another factor responsible for the rise of this segment is the availability of super-specialty expertise in these clinics.
INSIGHTS BY GEOGRAPHY
North America is growing at a healthy rate and this trend is likely to continue during the forecast period. The growth is due to the growing preference for HPV tests to detect and screen cervical cancers and other related infections. The US is the major revenue contributor to the North America HPV testing market. The region accounted for a share of 95% in 2019.
The HPV testing market share in Europe is the second-largest and accounted for a 24% share in 2019. Germany, France, the UK, Spain, and Italy are the leading contributors to the Europe region.
The APAC region has the highest population with a high risk of developing cervical cancers and other associated infections. Japan, China, Australia, South Korea, and India are the major revenue contributors from the region. Japan is the major revenue contributor to the HPV testing market in APAC. The growth is due to advancements in healthcare infrastructure, the rise in healthcare expenditure, and favorable public and private initiatives for an increase in healthcare access.
INSIGHTS BY VENDORS
The global HPV testing market share is highly competitive and characterized by the presence of several global, regional, and local players. F. Hoffmann-La Roche, QIAGEN, Hologic, and Abbott are the dominant players. Their testing instruments and consumables are widely used by end-users globally. These companies have a wide geographic footprint, diversified product portfolio, and a strong focus on innovation and research activities. Over the years, these players have been dominating the market as they have introduced safe and efficient products in the market.
The global HPV testing market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:
Market Segmentation by Products
- Cervical Cancers
- Vaginal Cancers
- Standard Reference Laboratories
- Physicians’ Office and Clinics
- North America
- South Korea
- Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia